Agomab Therapeutics NV Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand how Agomab Therapeutics performed this year. Instead of digging through dense filings, we’ll break down what’s happening so you can decide if it fits your investment goals.

1. What does this company do?

Agomab Therapeutics is a Belgian biotech company focused on treating fibrotic diseases. They work to regenerate damaged tissue and stop scarring by targeting the HGF/c-MET pathway. Because they are still testing their treatments, they do not sell products yet. Their main output is clinical data. This year, they went public on the Nasdaq (AGMB) to raise the capital needed to fund their research.

2. Financial performance

Agomab is in the research phase. They do not have commercial sales, so they are currently operating at a loss to fund their clinical trials. As of December 31, 2025, they had approximately 34.2 million shares outstanding. Their balance sheet includes "contingent considerations," which are future payments owed to partners if they hit specific scientific or regulatory goals. To manage cash flow, they pay staff partly with stock options. While this aligns the team’s interests with yours, it means additional shares may be issued later, which could reduce your ownership percentage.

3. Major wins and challenges

The biggest win was successfully launching their IPO and joining the Nasdaq, which provides better access to funding. Their primary challenge is their "burn rate"—the high cost of running clinical trials and labs before they have a product to sell. As a new public company, they are also navigating the requirements of U.S. reporting and cybersecurity standards to protect their research and satisfy regulators.

4. Financial health

We measure Agomab’s health by its "runway," or how long their cash will last. Beyond daily operational costs, they manage long-term lab leases and complex financial tools like anti-dilution warrants. These warrants protect early investors from having their ownership percentage reduced in future funding rounds. However, these warrants add accounting complexity and could lead to the issuance of more shares, which affects existing shareholders.

5. Key risks

Drug development is a high-stakes endeavor. If clinical trials fail to prove a drug is safe or effective, the company’s primary assets could lose their value, making it difficult to raise additional capital. As a public company, Agomab also faces intense scrutiny. Failure to meet U.S. financial reporting standards could impact investor trust or lead to delisting, both of which would hurt their ability to fund operations.

6. Competitive positioning

Agomab operates in a specialized niche. Their edge is a proprietary platform targeting the HGF/c-MET pathway. This focus sets them apart from large pharmaceutical companies that often take a broader, less targeted approach. This specialization makes their research pipeline a potential candidate for future partnerships or licensing deals with larger firms.

7. Future outlook

The company’s future depends on hitting key milestones, specifically positive results from their clinical trials. Success relies on two factors: proving their science works and managing their cash carefully so they have enough runway to reach these goals without needing to raise money on unfavorable terms.

Investor Takeaway: Agomab is a classic "all-or-nothing" biotech play. You aren't buying them for current revenue; you are buying them for the potential of their clinical data. If you are considering an investment, ask yourself if you are comfortable with the high risk of clinical trial outcomes and the potential for future share dilution as they continue to fund their research.